Arabic Arabic English English French French German German
dark

Gamma Biosciences Acquires Controlling Stake in Mirus Bio to Expand Reach in Gene Therapy and Next Generation Vaccines

— Lipid-polymer nanocomplexes (LPNCs) developed by Mirus enable superior transfection performance in a range of delivery applications
— Investment will support GMP launch of TransIT VirusGEN for high-productivity, cell-adaptive transfection in viral vector manufacturing
— Highly complementary engineering and delivery capabilities extend Gamma’s advanced therapy offering Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Idera Pharmaceuticals Announces Corporate Updates

Next Post

Agilex Biolabs’ Toxicology Tapped for SARS-CoV-2 Vaccine Research

Related Posts
Total
0
Share